Article

Patients with an unknown primary aren't getting the help they need

Author(s):

Surprise, surprise: not knowing where your cancer started can really stress you out.This not-so-unexpected news comes from a survey of members of the Association of Oncology Social Work. Reported at the AOSW's annual meeting in May, the survey found that 81 percent of oncology social workers found cancers of unknown primary to be more distressing, significantly more distressing, or extremely distressing for their patients compared with patients who received a specific diagnosis.Some more numbers: 38 percent of social workers said the greatest challenge for CUP (that's cancer of unknown primary) patients is a general fear associated with battling something unknown. Almost just as many say patients are most troubled by the lack of a definitive therapy, while about one in five reported that patients exhibit frustration and/or anger that their cancer can't be identified.Seeing as how only about 2 percent of respondents said they felt "very well prepared" to address a patient's distress, what the survey boiled down to, according to its authors, was that social workers need better training and resources to help these patients manage the psychological impact of their cancers. Any social workers out there want to weigh in?The survey was conducted by bioTheranostics, which markets Theros CancerTYPE ID – a molecular test for determining the origin of CUP cases. We're planning to get into this more in CURE's upcoming Summer issue, which drops at the end of June. Until then, any CUP patients have advice or experiences to share?

Related Videos
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Related Content